Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “STOKE THERAPEUTICS, INC.”

8 pharma patents match "STOKE THERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 8
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 8 pharmaceutical patents matching "STOKE THERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

8 results for “STOKE THERAPEUTICS, INC.” · 30,257 patents in full index Clear search

  1. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  2. US 12060558

    Methods and compositions for treatment of cholesteryl ester storage disease

    STOKE THERAPEUTICS, INC. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  3. US 11873490

    Antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted
  4. US 11814622

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  5. US 11096956

    Antisense oligomers and uses thereof

    STOKE THERAPEUTICS, INC. · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted
  6. US 11083745

    Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome

    STOKE THERAPEUTICS, INC. · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  7. US 10913947

    Antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted
  8. US 10683503

    Antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted